LGM
ORIC icon

Logos Global Management’s Oric Pharmaceuticals ORIC Stock Holding History

Logos Global Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
950,000
+500,000
+111% +$5.68M 0.6% 45
2025
Q4 		$3.68M Buy
+450,000
New +$5.18M 0.22% 58

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Logos Global Management's ORIC Position: Q1 2026 in Review

Logos Global Management increased its Oric Pharmaceuticals (ORIC) stake by 111% in Q1 2026, buying an estimated $5.68M and bringing the position to 950,000 shares worth $12M. The position accounts for 0.6% of the portfolio, ranked #45.

Logos Global Management first reported a position in ORIC in Q4 2025 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Logos Global Management held 950,000 shares of Oric Pharmaceuticals worth $12M as of Q1 2026.
  • Logos Global Management bought 500,000 Oric Pharmaceuticals shares in Q1 2026, an estimated $5.68M.
  • Oric Pharmaceuticals made up 0.6% of Logos Global Management's portfolio in Q1 2026, its #45 holding.
  • Logos Global Management first reported a position in Oric Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.